The clinical usefulness of the Sokolow-Lyon voltage criteria in the assessment of electrocardiographic left ventricular hypertrophy (ECG LVH) is addressed. We prospectively studied 3338 women and 3330 men referred with hypertension, with an average follow-up of 11.2 years. The voltage amplitude sum SV1 þ max (RV5 or RV6) was calculated and ECG LVH was defined as a sum X3.5 mV. We adjusted survival for age, treatment status before presentation and a previous myocardial infarction or cerebrovascular accident. The risk of stroke, coronary heart disease (CHD) and cardiovascular disease (CVD) mortality increased significantly for each quantitative 0.1 mV increase in baseline electrocardiogram (ECG) voltage, in women within the range of 1.6-3.9% and in men 1.4-3.0%. After further adjustments for race, body mass index, smoking and systolic blood pressure, increasing voltage independently predicted CVD mortality in both men and women. In women, both increasing voltage and the presence of left ventricular hypertrophy (LVH) were predictors of stroke mortality, whereas in men this risk was attenuated. In men, the adjusted association between increasing voltage and CHD mortality tended to be stronger than in women. The use of different thresholds for the two genders made little difference. For stroke and CHD mortality, the population attributable fractions associated with LVH were 15.2 and 5.4% in women and 12.8 and 8.5% in men, respectively. In conclusion, the greater the baseline ECG voltage sum, the greater the associated CVD mortality risk. Women tended to have a high risk of stroke mortality owing to LVH despite adjustments.
Introduction
The presence of left ventricular hypertrophy (LVH) in a hypertensive patient is evidence of hypertensive target organ damage, 1,2 although a number of factors other than blood pressure are known to be involved in the development of LVH. 3 Left ventricular hypertrophy has been shown to be associated with a significant increase in risk of cardiovascular mortality among the general population and hypertensive patients, independently of whether it is determined by electrocardiogram (ECG LVH), echocardiography (ECHO LVH) or radiology. 2, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Echocardiography is the gold standard for assessing anatomical LVH. 2, 14 However, it is less readily available and sometimes difficult to perform in obese and elderly subjects. 12, 15 Because of availability and low cost, the ECG has traditionally been the principal method for recognising LVH 1 and it provides additional information about cardiac rhythm, conduction and ischaemia. The commonly used Sokolow-Lyon voltage criteria 16 are very easy to employ in the assessment of LVH. Despite the high specificity, the ability of Sokolow-Lyon ECG voltage criteria to detect anatomical ECHO LVH or the increased left ventricular mass measured by autopsy is relatively low compared with several different ECG criteria. 14, 17 The question has therefore been asked, whether or not the low sensitivity limits its clinical utility. 17 Although there are surprisingly few studies concerning the prognostic effect of employing only the ECG method, in recent guidelines, Sokolow-Lyon ECG voltage criteria are still on the list of routine tests to determine target organ damage, together with the Cornell index. 1 In this study, we assessed the long-term mortality from stroke, coronary heart disease (CHD) and cardiovascular disease (CVD) with an increase in baseline Sokolow-Lyon ECG voltage among hypertensive women and men. We also compared the risk of mortality among subjects with and without LVH at baseline. The independent effect of LVH on mortality was studied after adjustments for confounders, especially for specified blood pressure levels.
Materials and methods
The Department of Health and Social Security Hypertension Care Computer Project (DHCCP) is a multicentre computer-based observational study, started in 1971, of patients being treated for hypertension in the United Kingdom. 18, 19 The DHCCP contains records of 11 663 patients referred with hypertension and recruited up to December 31, 1987 . Ninety-five per cent of patients entered the system on presentation to one of the hospital clinics (Hammersmith Hospital, London; King's College Hospital, London; John Radcliff Hospital, Oxford; City Hospital, Birmingham; Aberdeen Royal Infirmary). The remaining 5% were recruited from the general practices involved in the study (Kentish Town, London; Harlow; Oxford and Norwich).
The present analytical database was created on December 31, 1986 and 1477 patients presenting after this date were excluded. Of the remaining 10 186 subjects, 6698 subjects had an ECG recorded at entry. At presentation, 30 subjects were excluded from the analyses: 25 patients who were aged below 18 years and five in whom gender was not recorded. Thus, the results presented in this report refer to a database of 6668 patients from the DHCCP. The mean age of all subjects was 50.9 years (range 18.0-89.8 years).
The assessors were trained by clinical doctors familiar with ECGs and they evaluated the standard 12-lead resting ECGs according to the SokolowLyon criterion at presentation. All ECGs had a 1 mV calibration signal. The voltage sum SV1 þ max (RV5 or RV6) was calculated for the analyses using ECG voltage as a continuous variable. Electrocardiographic left ventricular hypertrophy was diagnosed when the voltage amplitude sum of either SV1 þ RV5 or SV1 þ RV6 at baseline was equal to or above 3.5 mV. Body mass index (BMI) was calculated as weight (kg)/height squared (m 2 ). Blood was not necessarily taken in the fasting state. Blood glucose measurements at baseline were not formally standardised although they were performed in laboratories linked to the United Kingdom quality assurance scheme. Smokers were those who currently smoked or who had smoked in the past. Blood pressure measurements were not formally standardised but were performed by experienced observers. Most observers used phase V Korotkoff as diastolic blood pressure (DBP). Baseline systolic blood pressure (SBP) and DBP measurements were those taken closest to the presentation or as the most recent measurement before presentation while not on antihypertensive drug treatment, and were available in 6237 subjects (Table 1) . Follow-up SBP and DBP were assessed during the first year of follow-up (N ¼ 4442). For 2768 patients, antihypertensive drug treatment had been started before presentation and for 5205 by 1 year of follow-up.
All patients were registered with the offices of National Statistics for England and Wales or the Registrar General for Scotland, who provided copies of the death certificates. Codes 4300-4389 were classified as stroke deaths, codes 4100-4149 as CHD deaths and codes 3900-4589 and 7950-7959 as CVD deaths (International Classification of Diseases, eighth revision). These analyses are based on an average of 11.2 years of follow-up. Abbreviations: BMI, body mass index; DBP0, baseline diastolic blood pressure (DBP); DBP1, follow-up DBP; LVH, left ventricular hypertrophy; LVH (%); proportion of subjects with LVH, N, number of subjects in whom information of each variable is available; P, P-value for statistical significance; previous cv disease, previous history of myocardial infarction or cerebrovascular accident; SBP0, baseline systolic blood pressure (SBP); SBP1, follow-up SBP; s.e., standard error.
Statistical methods
In descriptive analyses, the differences in mean values and standard errors among subjects with or without ECG LVH were compared using Student's t-test. Comparisons between proportions were performed using the w 2 test for independent groups. Multivariate analyses were performed by using the Cox proportional hazards model. 20 The estimates of relative risks and their 95% confidence intervals were calculated from this model. The relative risk of mortality for each 0.1 mV increment in baseline ECG voltage was calculated. In the categorical analysis, subjects with LVH were compared with the subjects without LVH. The analyses to estimate the relative risk of mortality were first adjusted for age, previous history of myocardial infarction or cerebrovascular accident and treatment status before presentation. To also control for the influence of BMI, smoking and race on mortality, we added these confounders simultaneously to a model in two subgroups of subjects, where the information on all of these variables was available (Groups 0 and 1). The additional variables were age, previous history of myocardial infarction or cerebrovascular accident, treatment status before presentation and baseline SBP (SBP0) in Model 0 (N ¼ 4530) or first-year follow-up SBP (SBP1) in Model 1 (N ¼ 3532). The variables in the analyses were selected from variables present in the vast majority of patients. Each of these variables was a significant predictor in a stepwise model for at least one end point either in women or in men.
The population attributable fraction (expressed as a percentage) for the excess deaths from stroke, CHD and CVD is the proportion of mortality associated with the presence of LVH. It was calculated as 100(IÀIc)/I, where I is the overall population risk of death and Ic is the expected risk of death for subjects who do not have LVH.
Statistical analyses were performed using the SAS statistical programs (The SAS Institute Inc., Cary, NC, USA).
Results
In this hypertensive population, the prevalence of ECG LVH defined using the above Sokolow-Lyon criterion was 14% among women and 25% among men ( Table 1) . The blood pressure of subjects with ECG LVH was higher, BMI was lower and they were more often black or a smoker than subjects without LVH. The subjects with LVH more often presented with a history of previous myocardial infarction or cerebrovascular accident and they were more often on antihypertensive drug treatment before presentation. The numbers and percentages dying from stroke, CHD and CVD stratified by the presence or absence of LVH in women and men are presented in Table 2 . During a mean follow-up period of 11.2 years, there were a total of 305 deaths from strokes, 611 from CHD and a total of 1087 CVD deaths.
After adjustments for age, treatment status before presentation and previous myocardial infarction and cerebrovascular accident, there was a significant increase in the relative risk of fatal stroke, CHD and CVD with each 0.1 mV increase in baseline ECG voltage (SV1 þ max (RV5 or RV6)) in both genders over an average of 11.2 years of follow-up (Table 3) . In women, the increase in the risk ranged from 1.6 (CHD) to 3.9% (stroke). In men, these risk estimates tended to be lower than risk estimates in women varying from 1.4 (CHD) to 3.0% (stroke). When LVH was expressed as a categorical variable, the risk associated with the presence of ECG LVH after these adjustments ranged from 1.3 (CHD) to 2.1 (stroke) in women and from 1.3 (CHD) to 1.5 (stroke) among men (Table 3) . Only the 1.3-fold risk of CHD mortality in women did not achieve statistical significance (P ¼ 0.17).
In women, controlling for all seven variables including baseline (Group 0, Model 0) or follow-up SBP (Group 1, Model 1), each 0.1 mV increase in ECG voltage was associated with an independent 2.7-3.6% increase in the risk of stroke mortality and 1.7-1.8% increase in the CVD mortality. The increase in the risk of CHD mortality was not statistically significant and adjustments for both baseline and follow-up SBP further attenuated these risk estimates (Table 4) .
In men, after full adjustments including baseline (Group 0, Model 0) or follow-up SBP (Group1, Model 1), each 0.1 mV increase in ECG voltage was associated with a significant 1.3-1.4% increase in the risk of CVD mortality. Adjustments for age and follow-up SBP partly attenuated the risk of stroke mortality. The increase in the risk of CHD mortality was partly dependent on baseline SBP (Table 4) .
In women, the presence of LVH was associated with a 1.6-fold (95% Cl 1.0-2.6, P ¼ 0.0679) adjusted risk of stroke mortality in Model 0 and 1.9-fold (95% Cl 1.1-3.3, P ¼ 0.0239) risk in Model 1 (data not shown). The risk of CVD mortality was 1.3-fold in Model 0 (95% Cl 1.0-1.8, P ¼ 0.0518) and 1.4-fold in Model 1 (95% Cl 1.0-1.9, P ¼ 0.0520). The adjusted nonsignificant risk of CHD mortality for women was 1.2 in Model 0 and 1.1 in Model 1. In men, the adjusted risks of stroke, CHD and CVD mortality 
Stroke 42 (9) 112 (4) 53 (6) 98 (4) CHD 44 (10) 189 (7) 120 (14) 258 (10) CVD 105 (21) 368 (13) 198 (23) 416 (17) Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; LVH, left ventricular hypertrophy.
associated with the presence of LVH ranged from 1.1 to 1.3 without statistical significance (data not shown).
After adjustments for baseline or follow-up DBP instead of SBP, the relative risks associated with increasing ECG voltage or with the presence Abbreviations: CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; Group 0, information on baseline systolic blood pressure (SBP0) available; Group 1, information on systolic blood pressure during the first year of follow-up (SBP1) available; P, P-value for statistical significance; RR, relative risks; SBP0, baseline systolic blood pressure (SBP); SBP1, follow-up SBP.
a All RR adjusted also for past history of myocardial infarction and cerebrovascular accident and for antihypertensive drug treatment before baseline. Also adjusted for race, body mass index, smoking and SBP0 in Model 0 (or SBP1 in Model 1).
of LVH remained virtually unchanged (data not shown).
The mean blood glucose concentration at baseline in women without LVH was 5.38 mmol/l and in women with LVH 5.25 mmol/l. The corresponding values in men were 5.38 and 5.26 mmol/l. When differences in age, treatment status and previous myocardial infarction and cerebrovascular accident were taken into account, an additional adjustment for blood glucose level or heart rate did not affect the magnitude of the risk of stroke and CVD-associated LVH in Table 3 . Adjustment for blood glucose level attenuated the risk of CHD associated with increasing ECG voltage in both women (RR ¼ 1.015, P ¼ 0.09) and men (RR ¼ 1.010, P ¼ 0.1520) as did adjustment for heart rate for the risk of CHD in women (RR ¼ 1.013, P ¼ 0.07) (data not shown).
The population attributable fraction for women associated with LVH was 15.2% for stroke, 5.4% for CHD and 9.3% for CVD mortality. For men, the corresponding percentages were 12.8, 8.5 and 9.2%, respectively.
Discussion
In women, a statistically significant and independent increase in the risk of stroke and CVD mortality was associated with increasing ECG voltage at baseline. The presence of LVH was also a significant risk factor for stroke in women in Model 1 and marginally significant in Model 0. Similarly, men had an independent increase in the risk of overall CVD mortality associated with increasing baseline ECG voltage. In men, adjusting for baseline SBP partly attenuated the effect of LVH on the risk of CHD mortality, whereas follow-up SBP attenuated the effect on the risk of stroke mortality. The adjustments for DBP only had a minor effect on the risk of mortality. In our study, the continuous voltage variable was found to be, as expected, a better predictor because, unlike a dichotomous variable, it retains all the information. However, for a clinician, it is easier to work with a cutoff value, even if this is slightly less good as a predictor.
Initially, in the Framingham study, the presence of ECG LVH predicted an increase in the risk of stroke, cardiac failure, coronary, peripheral vascular, total cardiovascular diseases and sudden death.
2,21 Subsequently, several studies have found an independent increase in mortality from CHD, 6-9 stroke 4, 6, 9, 22 and CVD 5,10,11,23 associated with ECG LVH among both the general population and hypertensive patients. A limitation in making comparisons between these studies is the fact that the ECG criteria used to determine LVH varied substantially between studies.
There are few published reports on the risk of cardiovascular mortality associated with ECG-LVH using Sokolow-Lyon ECG voltage sum SV1 þ max (RV5 or RV6) as the sole criterion. 10, 11, 24, 25 The European Working Party on High Blood Pressure Study (EWPHE) did not find any significant correlation between LVH and total or CVD mortality during a 4-year follow-up. 24 In the Italian Section of the Seven Countries Study, the association between non-sudden CHD mortality and LVH was even inverse. 25 The Progetto Ipertensione Umbria Monitoraggio Ambulatoriale (PIUMA) Study compared the prognostic value of different ECG LVH criteria among patients with essential hypertension. 10 During an average of 3.3 years of follow-up, a 1.8-fold increase in CVD mortality associated with the presence of ECG LVH by Sokolow-Lyon criteria was not statistically significant, whereas some newer criteria identified a significant risk. In a study of Swedish men, 11 the presence of LVH defined using the Cornell product independently predicted CVD and all cause mortality, whereas using SokolowLyon criteria, LVH only significantly predicted all cause mortality. In the study from the Glasgow Blood Pressure Clinic, 9 the presence of ECG LVH was diagnosed when the sum of SVI þ RV5 was above 35 mm or additionally the deepest precordial S and tallest R were above 40 mm. After adjustments, a significant increase in the risk of CHD and stroke mortality associated with the presence of ECG LVH was demonstrated among both hypertensive women and men. In the Framingham Study, 21 subjects with ECG LVH (one criterion or a combination of several voltage criteria together with repolarisation abnormalities) had an increased risk of CHD compared with all subjects, whereas the risk among subjects with only voltage criteria for ECG LVH did not remain significant. Of these tracings, 85% fulfilled the Sokolow-Lyon voltage criterion SV1 þ RV5X3.5 mV. The protocols of these studies 9-11,21,24 differed from our study in several ways: among others, the number of subjects with ECG LVH defined using Sokolow-Lyon criteria was smaller and the follow-up shorter than in our study. The participants in the study of Swedish men 11 and in the PIUMA Study 10 had lower mean blood pressure levels than subjects in the Glasgow Study 9 and in the present study. Hsieh et al.
26 compared the effect of 17 different LVH ECG criteria among 19 434 male veterans. No single criterion was significantly superior for predicting CVD mortality. Using selected Sokolow-Lyon criteria ((SV1 þ RV5)X3.5, RV5/ 6X2.6, RaVLX1.1 or RaVFX2 mV), the adjusted hazard ratio for CVD mortality was 1.9 (95% Cl 1.6-2.2) and higher than the corresponding relative risk estimates among men in our study. 26 The present study demonstrates the value of LVH defined solely by the Sokolow-Lyon voltage criterion SV1 þ max (RV5 or RV6) X3.5 mV as a predictor of stroke mortality especially among hypertensive women. Moreover, the population attributable risk was highest for stroke mortality among women (15%). It is not surprising that LVH predicts death from stroke, as both LVH and stroke have a close relationship with blood pressure level.
1,2 Both hypertension and ECG LVH have been shown to predict the development of atrial fibrillation, which is itself a major independent risk for stroke. 27 In our study, information on the presence of atrial fibrillation was not available at baseline or during follow-up.
The gender-specific risk of dying from cardiac causes has been reported to be higher among women than among men with ECHO LVH. 28 The Framingham study found higher risk estimates for CHD, stroke and any CVD morbidity for women versus men with ECG LVH, 2 whereas in a Belgian study the risk of CVD mortality was statistically significant among men only. 5 In the Glasgow Blood Pressure Clinic, ECG LVH among men was associated with a significant 2.7-, 1.8-and 1.6-fold risk of dying from ischaemic heart disease, stroke and all causes. The corresponding relative risks among women were 2.0, 4.0 and 2.4, respectively. 9 Similarly, the present study suggests that women with ECG LVH may have a relatively greater increase in the risk of stroke death than do men, whereas the adjusted risk of CHD mortality seems to be higher in men.
According to the guidelines in the 1980s, the decision to begin drug treatment was largely based on DBP and male gender has been one of the associated risk factors that influenced the decision to begin drug treatment at lower DBP levels. 29 In our study, the mean SBP levels as well as the mean age at presentation were higher among women than among men. It is possible that less active antihypertensive treatment strategies among women led to these differences in blood pressure levels between men and women and to the tendency for higher risk estimates of stroke mortality associated with LVH among women than among men in our study. An earlier and more effective antihypertensive treatment may be required to reduce the risk of stroke mortality especially in women. However, adjustments for SBP did not remove the excess risk of stroke or CVD associated with increasing voltage among women.
Echocardiographic left ventricular hypertrophy may be more common among middle-aged and older women than among men. 30 However, the sensitivity of the 3.5 mV Sokolow-Lyon criterion to detect anatomical LVH may be lower in women than in men, the former having lower voltages, particularly in the younger age ranges. This is complicated by the fact that the sensitivity of ECG LVH criteria will vary depending on other factors such as age, BMI or severity of LVH. 30, 31 The question remains, whether or not the presence of ECG LVH in our study identifies a more serious anatomical LVH with a greater risk in women than in men. Therefore, we additionally assessed the risk associated with the presence of LVH using the new gender-specific partition values for Sokolow-Lyon criteria for LVH (X3.4 mV for women and X3.8 mV for men) proposed by Alfakih et al. 32 The risk estimates using the new partition values remained similar to the estimates in Table 3 . In both genders, only the 1.3-fold risk for CHD mortality did not achieve statistical significance (data not shown). After full adjustments, only the 1.8-fold risk of stroke in women in Model 1 remained statistically significant (P ¼ 0.0343). Thus, the gender difference may simply reflect a superiority of the Sokolow-Lyon criteria to predict stroke in women compared with men, with the possibility that a lower voltage sum in women indicates a higher degree of hypertrophy than in men. Although the confidence limits for the relative risks in women and men overlap, the suggestion of differential prediction is supported by the tendency for the criteria to be a better predictor of CHD in men. This concept is supported to a large extent by the three studies discussed above. 2, 5, 9 Non-insulin-dependent diabetes mellitus has been independently associated with an increase in left ventricular mass. 33, 34 In our previous study among DHCCP patients, blood glucose concentration tended to be inversely related to the presence of ECG LVH by Sokolow-Lyon criterion. 35 In the Framingham Heart Study after adjusting for BMI and other risk factors, severity of hyperglycaemia was observed to be related to left ventricular mass more strongly in women than in men. 36 In the present study, the blood glucose level was measured in 3970 subjects and heart rate in 5862 subjects. After adjustments for variables in the Table 3 , additional adjustment for blood glucose level did not affect the magnitude of the LVH-associated risk of stroke and CVD mortality, but further attenuated the association between CVD mortality in both sexes.
Physical activity may be an important factor for physiological LVH especially in younger people. 2 In our study, the same voltage threshold to detect LVH was used for both young and old subjects. To exclude the effect of a possible physiological LVH in younger people, an additional analysis was restricted to women (N ¼ 2621) and men (N ¼ 2603) aged 40 years or more. In these analyses, the adjusted relative risks of mortality associated with both increasing voltage and the presence of LVH remained similar to the results in women and men aged 18 years or more. However, a 1.4-fold risk of CVD mortality in women reached statistical significance in both Model 0 and Model 1 (data not shown).
Electrocardiographic left ventricular hypertrophy has also been shown to diminish in parallel with a reduction in blood pressure level. 8, 37, 38 The results of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) Study 39 in patients with ECG LVH demonstrated that the risk of cardiovascular morbidity and death, especially the risk of stroke, was lower and reversing LVH more effective in those assigned losartan than assigned atenolol treatment. Regression of LVH by Sokolow-Lyon voltage criteria has been shown to result in a reduction of comorbidity in some 40, 41 but not in all studies. 42 In elderly patients with systolic hypertension in the Systolic Hypertension In Europe (Syst-Eur) Trial, a decrease in ECG voltage (RaVL þ SV1 þ RV5) independently predicted a lower incidence of cardiac events. 23 In our study, it was not possible to unequivocally exclude the effect of antihypertensive drug treatment on the gender difference in the risks of mortality. Diuretic treatment was significantly more prevalent in women than in men, 48.1 and 44.8%, respectively (P ¼ 0.007). On the other hand, angiotensin-converting enzyme (ACE) inhibitor use was less prevalent in women than in men, 6.0 and 7.3%, respectively (P ¼ 0.036). We analysed the data after we had excluded subjects on ACE inhibitors (N ¼ 442) and we also determined the relative risk of mortality adjusted for diuretic treatment. In both analyses, as well as in analyses where subjects with a history of myocardial infarction were excluded, the relative risks remained virtually the same as the risks in Table 3 .
The absence of ECG LVH by the Sokolow-Lyon criterion does not exclude the presence of anatomical LVH. On the other hand, ECHO LVH and ECG LVH have been shown to predict mortality independent of each other. 11 These findings suggest that anatomical ECHO and electrical ECG diagnoses of LVH might reflect certain differences in pathogenesis.
2,11 The Sokolow-Lyon voltage index SV1 þ max (RV5 or RV6) in hypertensive subjects is very commonly used, inexpensive to measure and very easy to employ. Despite its limited sensitivity, the data in our study support the clinical utility of the Sokolow-Lyon criterion. However, in patients in whom LVH is not discovered by this investigation, other recommended tests 1 should be employed to determine the overall cardiovascular risk for antihypertensive treatment strategies.
The sensitivity of ECG LVH by Sokolow-Lyon criteria to recognise ECHO LVH among obese subjects, particularly obese women, has been reported to be especially low. 16 We have discussed in detail the association between BMI and LVH in our previous paper. 32 We plan to estimate survival in both obese and non-obese hypertensive subjects, with the Sokolow-Lyon voltage criterion for LVH.
Strengths and limitations
The main strength of our study is the high number of hypertensive subjects with information on the presence or absence of ECG LVH, as defined by the commonly employed Sokolow-Lyon criterion. Untreated blood pressure was often measured only once. However, patients were referred with hypertension to the study and so the single blood pressure measurement might not overestimate the patient's usual blood pressure level, as these subjects will have been accustomed to blood pressure recording. In the 1980s, although controlled prospective studies on the effectiveness and safety of treatment of SBP were lacking, the recommendations on antihypertensive treatment were based on DBP. 33 As most patients referred with hypertension between 1971 and 1986 presented with elevated DBP, this study clearly was biased towards diastolic hypertension. Long-term mortality data were obtained from death certificates, known for their potential inaccuracies. Information on baseline SBP was available in 94% of subjects, follow-up SBP in 67%, variables in Model 0 in 65% and in Model 1 in 49% of subjects. Thus, the adjusted results do not reflect all the patients. Also, ECG LVH at baseline was not always measured at the same time as baseline blood pressure and the latter may have been determined some time previously. However, these discrepancies are likely to lead to falsely negative results and not to the positive findings of the study. Also, in this study, it was not possible to compare the effect of LVH measured using Sokolow-Lyon criteria with other ECG measurements for LVH on mortality.
In conclusion, in both men and women, the greater the baseline voltage sum, the greater the associated CVD mortality risk. Women remained with a high risk of stroke mortality due to LVH despite adjustments.
